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1 -3 Anderson 4 described 18 patients with heart defects after prenatal exposure to hydantoin, some of whom were also exposed to other anticonvulsants. The most common anomaly was ventricular septal defect, which was either isolated or in association with other cardiac anomalies, especially pulmonic stenosis. One patient had transposition of the great arteries. However, this patient was also prenatally exposed to phenobarbital. Friis and Sardemann 5 described two patients with neonatal hypocalcemia after prenatal exposure to hydantoin and phenobarbital. An effect on vitamin D metabolism was suggested; however, hypoparathyroidism was apparently not ruled out. We report a patient who was prenatally exposed to hydantoin alone and who had d-transposition of the great arteries (d-TGA) and persistent hypocalcemia. He also had some of the well-known anomalies of FHS. It is not clear how hydantoin could cause structural heart disease and hypocalcemia; however, we speculate that in our patient, there may have been a hydantoin effect on neural crest cell migration. 6 Disturbances of neural crest cell migration has previously been implicated in the DiGeorge/velocardiofacial syndrome, a condition often presenting with cardiac anomalies and hypocalcemia. 7, 8 When tested with fluorescent in situ hybridization, our patient did not have the chromosomal deletion associated with DiGeorge/velo-cardiofacial syndrome.
CASE REPORT
The patient was the third child of nonconsanguineous parents. The family history was negative for congenital heart defects, hypocalcemia, or other congenital anomalies. During the pregnancy, the mother took 200 mg of hydantoin orally twice a day. She did not have gestational diabetes during her pregnancy. The patient was delivered at 39 weeks' gestation and was appropriate for gestational age for weight, length, and head circumference. He was noted to have a depressed nasal bridge, coarse scalp hair, hirsutism, nail hypoplasia, and hypoplasia of the fifth digits bilaterally. Because of cyanosis at birth, an echocardiogram was performed and demonstrated d-TGA, atrial septal defect, patent ductus arteriosus, and an intact ventricular septum. He had persistent hypocalcemia (5.8 to 7.8 mg/dl; normal 8 to 10 mg/dl) for 4 weeks, which was corrected with calcium supplementation. The parathyroid hormone level was 39 pg/ml, which is in the low range. The thymus was visible on chest X-ray and T-and B-cell subsets were normal. Prometaphase karyotype at 550 band resolution level was normal. Using the DiGeorge region probe D22S75 (ONCOR), the patient did not have the 22q11.2 deletion when tested by fluorescent in situ hybridization. The patient has undergone corrective surgery for his heart defect. At the age of 5 months, he is still on calcium supplementation.
DISCUSSION
Our patient had several well-recognized features of FHS, but also had hypocalcemia and d-TGA, which have only rarely been reported. 4, 5 These previous reports were in patients also exposed to other anticonvulsants; therefore, ours is the first report of these problems with hydantoin exposure alone. We cannot exclude the possibility that the d-TGA and/or hypocalcemia were due to some other factor, unrelated to hydantoin. We considered the possibility of the DiGeorge/velo-cardiofacial syndrome; however, our patient did not have the deletion of 22q11.2, the chromosomal region responsible for this condition. We suggest that hypocalcemia be We report a patient with fetal hydantoin syndrome ( FHS ) with associated d -transposition of the great arteries ( d -TGA ) and persistent hypocalcemia. d -TGA and hypocalcemia have each been individually reported once in association with FHS, but these patients were also prenatally exposed to phenobarbital. To our knowledge, this is the first report of these problems occurring after prenatal exposure to hydantoin alone. The combination of congenital heart disease and hypocalcemia in our patient raises the possibility of a hydantoin effect on neural crest migration. considered an occasional feature of FHS and should be assessed in this patient.
Various mechanisms have been postulated to account for the effect of hydantoin on the developing embryo, including induction of fetal hypoxia leading to vascular disruption, interaction with the enzyme epoxide hydrolase locus, and more recently, a possible interaction of hydantoin with patterning genes such as members of the Hox family. 6,9 -11 Some Hox genes play a role in determining developmental specificity of migrating neural crest cells during embryogenesis. The parathyroid glands and cardiac outflow tract are formed, in part, by migration of neural crest cells from the branchial arches. 7, 12, 13 We speculate that a possible mechanism for the d-TGA and hypocalcemia in our patient was an effect by hydantoin on neural crest cell migration perhaps due to an interaction with specific members of the Hox family or related genes.
